Stay up to date

Call for Abstracts Open - 6th Global Forum on TB Vaccines

Mon, Sep 6, 2021

The Call for Abstracts for the 6th Global Forum on TB Vaccines is now open. Researchers, product developers, advocates, community representatives, and others interested and engaged in TB vaccine R&D are encouraged to submit abstracts to share new approaches, data, and results in TB vaccine R&D, policy, and access. Submitted abstracts will be considered for oral or poster presentation, and in-person and virtual presentation opportunities will be available. A limited amount of support will be available for in-person (where possible based on restrictions at the time) and virtual participation. More information about travel support and how to apply will be provided shortly.

Abstracts will be accepted through 15 October 2021

For more information 

AIDSImpact Webinar: The Nexus Between HIV and COVID-19, 22 April 2021

Sun, Apr 18, 2021

AIDSImpact is an international behavioral and psychosocial science conference that addresses issues related to HIV/AIDS prevention, treatment, and care, focusing both globally and on specific communities and countries hardest hit by the HIV/AIDS epidemic.

Join the 1st webinar on "The Nexus Between HIV and COVID-19." This webinar will take place on Thursday, 22 April 2021. Registration is provided complimentary by AIDSImpact.

For more information visit

3rd Scientific BCA-WA-ETHICS Congress on research ethics during the COVID-19 pandemic (French)

Wed, Mar 16, 2022 22 - 25 March 2022 | 10:00 - 14:00 GMT Virtual

World TB Day: the promise of ending the TB epidemic

Thu, Mar 25, 2021

World TB Day puts the spotlight on tuberculosis (TB), a poverty-related infectious disease of epidemic proportions. Currently, it causes more deaths than any other infectious disease, mostly in low- and middle-income countries. Every year, an estimated 10 million people fall ill; in 2019, 1.4 million people died from TB. All members of the United Nations committed to ending TB as an epidemic by 2030. However, the 2020 WHO progress report concluded that the world is not on schedule to achieve the 2022 targets. The COVID-19 pandemic even threatens to reverse recent progress towards global TB targets. Chronic global underfunding of TB research means that cheap, accessible point-of-care tests, better vaccines and simple, short treatment regimens are lacking. Ending TB depends on the development and rapid uptake of new tools and innovation.

“Our steady commitment to fight TB has led to a growing R&D portfolio of grants on novel diagnostics, more patient-friendly treatments, and experimental vaccines for pre-and post-exposure use – especially targeting vulnerable populations. Moreover, we have invested in international coordination of TB vaccine R&D, and preparation of ground for a new global TB vaccine roadmap. EDCTP is convinced a concerted global R&D effort will end TB.”
Dr Michael Makanga, EDCTP Executive Director

Visit to learn more about EDCTPs efforts to end TB.